Renalytix PLC on Monday said it expanded its insurance coverage base in the Northeast region of the US via a coverage contract with EmblemHealth, a non-profit health insurer with three million customers in the New York Tri-state area.

The London-based kidney health-focused diagnostics company said the contract builds on the comprehensive insurance coverage portfolio necessary to transition to a full commercial payment model for KidneyIntelX prognostic testing in New York state and Connecticut state.

Renalytix shares were 2.5% higher at 82.00 pence each in London on Monday morning.

Copyright 2023 Alliance News Ltd. All Rights Reserved.